3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Other neoplasm
1
Conditions
Hospice
1
Interventions
Whole-Body Irradiation
4
Sulindac
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
fludarabine phosphate
3
Selenium
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Cetuximab
3
Biopsy
3
Tacrolimus
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Polymerase Chain Reaction
2
Oxycodone
2
Mycophenolic Acid
2
Melphalan
2
Gene Expression Profiling
2
Etoposide
2
Darbepoetin alfa
2
Cyclosporine
2
Cyclophosphamide
2
Cisplatin
2
Busulfan
2
Aspirin
2
Aminolevulinic Acid
2
Albumin-Bound Paclitaxel
2
vandetanib
1
soybean oil, phospholipid emulsion
1
ruxolitinib
1
polyphenon E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Psilocybin
×
Other neoplasm
×
Clear all
NCT04950608
2026-02-17
PATH
Dana-Farber Cancer Institute
Phase 2
Completed
15 enrolled
26 charts